AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2.
AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan
May 22, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022